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Original Research Paper
Increased Cholesterol Found on Erythrocytes After ACS
The outer membranes of erythrocytes are heavily concentrated with free choles-terol. Some studies have found erythrocyte membranes inside atherosclerotic
lesions, suggesting a link with plaque cholesterol. Tziakas and colleagues studied the
extent to which cholesterol on erythrocytes correlates with several factors in patients
presenting for coronary angiography. Total cholesterol content in erythrocyte mem-
branes (CEM) was higher in acute coronary syndrome (ACS) patients compared to
those with stable angina. Interestingly, total plasma cholesterol concentrations did not
correlate with CEM levels. As part of a focus issue on Plaque Neovascularization,
Hemorrhage, andVulnerability, this study suggests that themake-up of atherosclerotic
lesions is dynamic andmay lead to a better understanding ofwhy someplaques rupture
while others remain quiescent. See page 2081. See figure.
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Interventional Cardiology
Worse Outcomes for Stenting if FFR >0.75
Percutaneous coronary intervention (PCI) of a visually significant stenosis withoutevidence of ischemia is often performed, but its benefit is unproven. TheDEFER
study randomized 325 subjects with an intermediate stenosis and a fractional flow
reserve (FFR) 0.75 to either PCI or no PCI. After 5 years, the composite rates of
cardiac death and acutemyocardial infarction weremore than twice as high in the PCI
group, 3.3%versus 7.9%.Five-year outcomesof coronary stenoseswith anFFR0.75
are excellent; the risk of cardiac death or myocardial infarction related to this stenosis
is1% per year and is not decreased by stenting. See page 2105. See figure.
Metabolic Syndrome
and Risk
Insulin Resistance May Drive Increased Risk With MetSyn
Insulin resistance (IR) is one of the hallmarks of the metabolic syndrome (MetSyn).Jeppesen and colleagues studiednearly 2,500Danishmen andwomen todetermine
if MetSyn or IR was the primary contributor to increased cardiac risk. Prevalence of
MetSyn according to International Diabetes Foundation (IDF) criteria was 21% and
16% according to NCEP criteria. The IR was defined as being in either the highest
21% or 16% in the homeostasis model assessment (HOMA). When the IDF criteria
were used,HOMA-IRbut notMetSynwas predictive of future events.UsingNational
Cholesterol Education Program criteria, both HOMA-IR andMetSyn were indepen-
dent predictors. While much is still unknown, this study suggests that IR leads to
increased cardiac risk, independent of the other criteria of the MetSyn. See page
2112.
(continued) A-32Preclinical Study
Novel Cardiac Electrical Stimulation Method May Improve LV Remodeling
Cardiac contractility modulation (CCM) is a novel therapy whereby the myocar-dium is stimulated with a pulse generator during the absolute refractory period.
Dogs with microembolization-induced heart failure were randomized to 3 months of
activeCCMmonotherapyor to a shamoperation.After 3months, the ejection fraction
(EF) of dogs treated with CCMwas 33%, while for control animals it was only 23%.
In a second study, animals were randomized to either CCM, metoprolol succinate, or
combination therapy. Dogs treated with combination therapy showed a greater in-
crease in left ventricular (LV) EF and a greater reversal of LV global, structural, and
biochemical remodeling compared with dogs treated with metoprolol alone. CCM
appears to be a promising therapy for heart failure with both short- and long-term
improvements in LV function. See page 2120.
